leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma says its R&G Relief & Go CBD Spray product successfully passes EU safety requirements

The product also has received a Cosmetic Product Safety Report for product marketing in the EU

InnoCan Pharma - Innocan Pharma Corporation says its R&G Relief & Go CBD Spray product has successfully passed safety requirements of the European Parliament and the Council on Cosmetic Products
The spray combines the known benefits of active ingredients such as menthol and camphor with CBD and magnesium to help the body relax and recover for sport-performing professionals

Innocan Pharma Corporation (CSE:INNO) (FRA:IP4) has announced that its R&G Relief & Go CBD Spray product has successfully passed detailed safety assessment requirements of the European Parliament and the Council on Cosmetic Products. 

The product also has received a Cosmetic Product Safety Report (CPSR) for product marketing in the EU, the company said in a statement Wednesday. 

READ: Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs

Wholly-owned subsidiary Innocan Israel’s patent-pending unique formulation spray combines the known benefits of active ingredients such as menthol and camphor with CBD and magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals.

Innocan Pharma noted that Nir Avram, the subsidiary’s CTO, has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Avram consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.

Nir is vice president of research & development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to that, he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.

"We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product," said Innocan Pharma CEO Iris Bincovich. "This is a major accomplishment for our team and an exciting milestone of our future".

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: InnoCan Pharma

Price: 0.225 CAD

CSE:INNO
Market: CSE
Market Cap: $39.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read